Firefly Neuroscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 14 Nov 2026 |
| FY 2026 Annual Earnings Release (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Standardized EEG/ERP Brain Scan Volume Quarterly200KTarget: Continued sequential growth (historically 5% to 17% QoQ)
Commercial Users Quarterly85.0Target: Expansion of commercial footprint and partner sites
Quarterly Revenue Quarterly485KTarget: Scale recurring subscription/lease model revenue
Watch Items
- Going Concern Uncertainty and Capital RunwayTrigger: Cash reserves falling below 6 months of operating expensesAction: Secure additional equity or debt financing, execute disciplined expense management, or pursue strategic partnerships.
- Commercial Transition of Evoke SystemTrigger: Slower-than-expected conversion from one-time product sales to subscription/lease modelAction: Re-evaluate sales incentives, adjust pricing tiers, and intensify direct sales outreach to clinical sites.
- Department of Defense (War) Partnership MilestonesTrigger: Failure to secure commercial pathways or clinical trial endpoints using the newly discovered PTSD biomarkerAction: Engage with military health administrators and pharmaceutical partners to integrate the PTSD biomarker into active protocols.
Research as of 20 Jun 2026